Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs ShedRx

By GLP-1 ScorecardUpdated

Kin MedsFactor scores not reassessed.
Site position #147

Lower score

ShedRx
Site position #3

Higher score

Score comparison

ShedRx has the higher recorded score — 87/100 to 69.1/100.

ShedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shed combines compounded injections and branded Wegovy/Zepbound options with coaching; compare longer-plan supply, fees and guarantee rules before committing.

Before you choose

Before comparing the headline prices, the Kin Meds review and the ShedRx review set out what each semaglutide figure in the table below covers, including whether the medication is a brand-name product billed by a pharmacy. Brand-name and compounded prices are different products, so set like against like before treating either one as cheaper.

If neither one fits, Kin Meds vs Wholesome Clinic and Klinic vs ShedRx compare each of them with another graded program, and the list of alternatives to Kin Meds ranks the programs closest to Kin Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueShedRx +10
74
84
Dose & formulationShedRx +3
93
96
Clinical oversightShedRx +29
55
84
Labs & monitoringShedRx +31
53
84
FulfillmentShedRx +16
72
88
Contract termsShedRx +30
55
85
Kin Meds · top barShedRx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricKin MedsShedRx
WeighScore69.1/10087/100
GradeCB+
Site position#147#3
SemaglutideWegovy advertised from $149/mo; selected total unverified$199/mo
TirzepatideZepbound advertised from $149/mo; selected total unverified$299/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualYesYes
Kin Meds

Site position #147 · C

Factor scores not reassessed.

FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.

Strengths

  • Lists Wegovy and Zepbound on separate product pages
  • Describes subscription cancellation through the patient account before shipment

What to consider

  • The advertised starting price leaves the selected bill and insurance costs unverified
  • The policy treats charged orders as final after carrier handoff
  • Confirm service availability and dispensing pharmacy for your prescription
  • FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database
ShedRx

Site position #3 · B+

Strengths

  • Published injection plans plus other formulation and branded prescribing options
  • One-month injection prices listed at $199 semaglutide / $299 tirzepatide
  • Terms describe monthly coaching and name six possible pharmacy partners

What to consider

  • Six- and twelve-month plans specify 24 and 48 weeks of medication
  • The 120-day promise has first-time-user and participation requirements and does not cancel a longer plan
  • Branded pages display conflicting $99/$125 membership charges, with medication separate
  • Actual clinician/pharmacy assignment and the applicable minimum term need confirmation

Featured provider

ShedRx

ShedRx scores 87/100 (B+). Shed combines compounded injections and branded Wegovy/Zepbound options with coaching; compare longer-plan supply, fees and guarantee rules before committing.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard